These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32727882)

  • 1. Tipifarnib as a Precision Therapy for
    Gilardi M; Wang Z; Proietto M; Chillà A; Calleja-Valera JL; Goto Y; Vanoni M; Janes MR; Mikulski Z; Gualberto A; Molinolo AA; Ferrara N; Gutkind JS; Burrows F
    Mol Cancer Ther; 2020 Sep; 19(9):1784-1796. PubMed ID: 32727882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
    Jagadeeshan S; Suryamohan K; Shin N; Mathukkada S; Boyko A; Melikhova D; Tsareva A; Yunusova L; Pravdivtseva E; Stupichev D; Shaposhnikov K; Peterson A; Bednyagin L; Shugaev-Mendosa E; Kessler L; Burrows F; Ho AL; Agrawal N; Pearson AT; Izumchenko E; Cole G; Elkabets M; Rosenberg AJ
    Oral Oncol; 2024 Feb; 149():106688. PubMed ID: 38219706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.
    Javaid S; Schaefer A; Goodwin CM; Nguyen VV; Massey FL; Pierobon M; Gambrell-Sanders D; Waters AM; Lambert KN; Diehl JN; Hobbs GA; Wood KC; Petricoin EF; Der CJ; Cox AD
    Mol Cancer Ther; 2022 May; 21(5):762-774. PubMed ID: 35247914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tipifarnib in Head and Neck Squamous Cell Carcinoma With
    Ho AL; Brana I; Haddad R; Bauman J; Bible K; Oosting S; Wong DJ; Ahn MJ; Boni V; Even C; Fayette J; Flor MJ; Harrington K; Kim SB; Licitra L; Nixon I; Saba NF; Hackenberg S; Specenier P; Worden F; Balsara B; Leoni M; Martell B; Scholz C; Gualberto A
    J Clin Oncol; 2021 Jun; 39(17):1856-1864. PubMed ID: 33750196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
    Smith AE; Chan S; Wang Z; McCloskey A; Reilly Q; Wang JZ; Patel HV; Koshizuka K; Soifer HS; Kessler L; Dayoub A; Villaflor V; Adkins DR; Bruce JY; Ho AL; Perez CA; Hanna GJ; Gascó Hernández A; Saunders A; Dale S; Gutkind JS; Burrows F; Malik S
    Cancer Res; 2023 Oct; 83(19):3252-3263. PubMed ID: 37339176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
    Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
    Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Coleman N; Marcelo KL; Hopkins JF; Khan NI; Du R; Hong L; Park E; Balsara B; Leoni M; Pickering C; Myers J; Heymach J; Albacker LA; Hong D; Gillison M; Le X
    JCO Precis Oncol; 2023 Jan; 7():e2200211. PubMed ID: 36603172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
    Shu L; Wang D; Nannapaneni S; Sun Y; Griffith CC; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM; Chen ZG; Saba NF
    Oral Oncol; 2021 Nov; 122():105546. PubMed ID: 34700281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.
    Wang J; Al-Majid D; Brenner JC; Smith JD
    Target Oncol; 2023 Sep; 18(5):643-655. PubMed ID: 37665491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.
    Desilets A; Ho AL
    Cancer J; 2022 Sep-Oct 01; 28(5):363-368. PubMed ID: 36165724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?
    Ben Yahia H; Petit FM; Saada-Bouzid E
    Curr Opin Oncol; 2023 May; 35(3):178-185. PubMed ID: 36966498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.
    Untch BR; Dos Anjos V; Garcia-Rendueles MER; Knauf JA; Krishnamoorthy GP; Saqcena M; Bhanot UK; Socci ND; Ho AL; Ghossein R; Fagin JA
    Cancer Res; 2018 Aug; 78(16):4642-4657. PubMed ID: 29760048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
    Hah JH; Zhao M; Pickering CR; Frederick MJ; Andrews GA; Jasser SA; Fooshee DR; Milas ZL; Galer C; Sano D; William WN; Kim E; Heymach J; Byers LA; Papadimitrakopoulou V; Myers JN
    Head Neck; 2014 Nov; 36(11):1547-54. PubMed ID: 24123531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
    Alsina M; Fonseca R; Wilson EF; Belle AN; Gerbino E; Price-Troska T; Overton RM; Ahmann G; Bruzek LM; Adjei AA; Kaufmann SH; Wright JJ; Sullivan D; Djulbegovic B; Cantor AB; Greipp PR; Dalton WS; Sebti SM
    Blood; 2004 May; 103(9):3271-7. PubMed ID: 14726402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors.
    Nigam A; Krishnamoorthy GP; Chatila WK; Berman K; Saqcena M; Walch H; Venkatramani M; Ho AL; Schultz N; Fagin JA; Untch BR
    Oncogene; 2024 Sep; 43(37):2806-2819. PubMed ID: 39152269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.
    Lee RH; Johnson DE; Grandis JR
    Cancer Res; 2023 Oct; 83(19):3162-3164. PubMed ID: 37779427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring
    Lee HW; Sa JK; Gualberto A; Scholz C; Sung HH; Jeong BC; Choi HY; Kwon GY; Park SH
    Clin Cancer Res; 2020 Oct; 26(19):5113-5119. PubMed ID: 32636318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.